Abdulla A, Sadida H, Jerobin J, Elfaki I, Mir R, Mirza S
J Natl Cancer Cent. 2025; 5(1):8-27.
PMID: 40040878
PMC: 11873641.
DOI: 10.1016/j.jncc.2024.11.001.
Li P, Lin Y, Ma H, Zhang J, Zhang Q, Yan R
Cell Death Discov. 2025; 11(1):43.
PMID: 39904996
PMC: 11794895.
DOI: 10.1038/s41420-025-02324-z.
Zhang K, Zhang F, Wang J
J Cancer Res Clin Oncol. 2025; 151(1):36.
PMID: 39820532
PMC: 11739181.
DOI: 10.1007/s00432-024-06073-x.
Wang S, Xuan Z, Chen Z, Xu P, Fang L, Li Z
Int J Biol Sci. 2025; 21(1):346-362.
PMID: 39744419
PMC: 11667809.
DOI: 10.7150/ijbs.97464.
Benak D, Sevcikova A, Holzerova K, Hlavackova M
Front Cell Dev Biol. 2025; 12:1500394.
PMID: 39744011
PMC: 11688314.
DOI: 10.3389/fcell.2024.1500394.
FTO Facilitates Cervical Cancer Malignancy Through Inducing m6A-Demethylation of PIK3R3 mRNA.
Chen B, Wang L, Li X, Ren C, Gao C, Ding W
Cancer Med. 2024; 13(24):e70507.
PMID: 39692250
PMC: 11653219.
DOI: 10.1002/cam4.70507.
Epitranscriptomic RNA mA Modification in Cancer Therapy Resistance: Challenges and Unrealized Opportunities.
Uddin M, Wang Z, Yang C
Adv Sci (Weinh). 2024; :e2403936.
PMID: 39661414
PMC: 11775542.
DOI: 10.1002/advs.202403936.
FTO-mediated demethylation of MTUS1/ATIP1 promotes tumor progression in head and neck squamous cell carcinoma.
Tang D, Cao C, Li W, Wang A
BMC Cancer. 2024; 24(1):1489.
PMID: 39627705
PMC: 11613461.
DOI: 10.1186/s12885-024-13253-y.
Decoding the epitranscriptome: a new frontier for cancer therapy and drug resistance.
Tang L, Tian H, Min Q, You H, Yin M, Yang L
Cell Commun Signal. 2024; 22(1):513.
PMID: 39434167
PMC: 11492518.
DOI: 10.1186/s12964-024-01854-w.
Epitranscriptomics and cervical cancer: the emerging role of mA, mC and mA RNA modifications.
Modi A, Zahid H, Southerland A, Modi D
Expert Rev Mol Med. 2024; 26:e20.
PMID: 39377535
PMC: 11488341.
DOI: 10.1017/erm.2024.20.
m6A modification of RNA in cervical cancer: role and clinical perspectives.
Gao Y, Guo Q, Yu L
RNA Biol. 2024; 21(1):49-61.
PMID: 39344658
PMC: 11445900.
DOI: 10.1080/15476286.2024.2408707.
FTO diversely influences sensitivity of neuroblastoma cells to various chemotherapeutic drugs.
Lin M, Hua Z, Li Z
Front Pharmacol. 2024; 15:1384141.
PMID: 39295930
PMC: 11409730.
DOI: 10.3389/fphar.2024.1384141.
Research progress on m6A demethylase FTO and its role in gynecological tumors.
Wang S, Liu Q
Front Oncol. 2024; 14:1413505.
PMID: 39175477
PMC: 11338917.
DOI: 10.3389/fonc.2024.1413505.
Single-nucleus and spatial transcriptome reveal adrenal homeostasis in normal and tumoural adrenal glands.
Altieri B, Secener A, Sai S, Fischer C, Sbiera S, Arampatzi P
Clin Transl Med. 2024; 14(8):e1798.
PMID: 39167619
PMC: 11338279.
DOI: 10.1002/ctm2.1798.
Examining the evidence for mutual modulation between m6A modification and circular RNAs: current knowledge and future prospects.
Tang X, Guo M, Zhang Y, Lv J, Gu C, Yang Y
J Exp Clin Cancer Res. 2024; 43(1):216.
PMID: 39095902
PMC: 11297759.
DOI: 10.1186/s13046-024-03136-2.
Functions and mechanisms of RNA mA regulators in breast cancer (Review).
Yang Y, Gao F, Ren L, Ren N, Pan J, Xu Q
Int J Oncol. 2024; 65(3).
PMID: 39054967
PMC: 11299767.
DOI: 10.3892/ijo.2024.5674.
Progression of mA in the tumor microenvironment: hypoxia, immune and metabolic reprogramming.
Han X, Zhu Y, Ke J, Zhai Y, Huang M, Zhang X
Cell Death Discov. 2024; 10(1):331.
PMID: 39033180
PMC: 11271487.
DOI: 10.1038/s41420-024-02092-2.
ZFHX3 acts as a tumor suppressor in prostate cancer by targeting FTO-mediated mA demethylation.
Hu Q, Yin J, Zhao S, Wang Y, Shi R, Yan K
Cell Death Discov. 2024; 10(1):284.
PMID: 38871709
PMC: 11176170.
DOI: 10.1038/s41420-024-02060-w.
Mechanisms and clinical landscape of N6-methyladenosine (m6A) RNA modification in gastrointestinal tract cancers.
Zhu D, Su K, Ou-Yang X, Zhang Y, Yu X, Li Z
Mol Cell Biochem. 2024; 479(7):1553-1570.
PMID: 38856795
PMC: 11254988.
DOI: 10.1007/s11010-024-05040-x.
Ferroptosis: a critical mechanism of N-methyladenosine modification involved in carcinogenesis and tumor progression.
Wei Q, Xue C, Li M, Wei J, Zheng L, Chen S
Sci China Life Sci. 2024; 67(6):1119-1132.
PMID: 38811442
DOI: 10.1007/s11427-023-2474-4.